In the UK CUtLASS 1 study there were no significant differences in rates of objectively assessed EPSEs between groups of patients receiving an FGA and an SGA, yet patients taking an FGA were more likely to be prescribed an anticholinergic medication.7,10 Similarly, the US CATIE study showed that SGAs were no better for EPSEs, negative symptoms or cognitive deficits.9 It is surprising that despite concerns about EPSEs, haloperidol, a potent dopamine D2 receptor antagonist, emerged as the most commonly used FGA in our survey. The gene discussed is DRD2; the disease is Cognitive impairment.